logo-loader

Heat Biologics doses first patient in its Phase 1 clinical trial evaluating anti-cancer drug PTX-35

Published: 12:27 22 Jun 2020 EDT

Heat Biologics, Inc subsidiary Pelican Therapeutics CEO Rahul Jasuja tells Proactive the clinical-stage biopharmaceutical company has dosed its first patient in its first-in-human Phase 1 clinical trial evaluating PTX-35 as an anti-cancer drug.

Jasuja says this first-in-human study is expected to enroll up to 30 patients with advanced solid tumors and is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Heat Biologics updates on its achievements in 2020, and expectations for 2021

Heat Biologics Inc (NASDAQ:HTBX) CEO Jeff Wolf talks to Proactive about how the Durham, North Carolina-based biotechnology company plans to proceed with its Phase 3 registration pathways for its lead therapy HS-110 in combination with a checkpoint inhibitor. What's more, Wolf spoke about the...

on 03/30/2021